Clinical Trial Update: Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial evaluates the PARP inhibitor olaparib, alone or with bevacizumab, for patients with ovarian, fallopian tube, or primary peritoneal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Lynparza (olaparib)

Snippet

Sponsor: NRG Oncology | Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Status: RECRUITING